# US 2015/0147763 A1 · Antibodies Against Claudin 18.2 Useful in Cancer Diagnosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147763 A1
- Document ID: US20150147763A1
- Status: Published application
- Kind: A1
- Application number: 14/397,244
- Filed: 2013-05-06
- Published: 2015-05-28
- Earliest claimed: 2012-05-09
- Assignees: Ganymed Pharmaceuticals AG; TRON- Translationale Onkologie an der Johannes Gutenberg-Universitat Mainz gemeinnutzige GmbH
- Applicants: Ganymed Pharmaceuticals AG; TRON- Translationale Onkologie an der Johannes Gutenberg-Universitat Mainz gemeinnutzige GmbH
- Inventors: Ugur Sahin; Özlem Türeci; Rita Mitnacht-Kraus; Stefan Wöll
- Web page: https://patentgrep.com/patent/US20150147763A1

## CPC

- C07K 16/30: from tumour cells
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/3023: {Lung}
- C07K 16/303: {Liver or Pancreas}
- C07K 16/3046: {Stomach, Intestines}
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.

## Claims

### Claim 1

An antibody or antigen-binding fragment thereof which
(i) binds to a peptide having the amino acid sequence TEDEVQSYPSKHDYV (SEQ ID NO: 5) or EVQSYPSKHDYV (SEQ ID NO: 6) and/or
(ii) binds to claudin 18.2 (CLDN18.2), wherein said antibody or antigen-binding fragment thereof binds to CLDN18.2 by binding at least to an epitope within CLDN18.2 having the amino acid sequence TEDEVQSYPSKHDYV (SEQ ID NO: 5) or EVQSYPSKHDYV (SEQ ID NO: 6).

### Claim 2 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein said CLDN18.2 is cell surface membrane-bound CLDN18.2.

### Claim 3 (depends on 1, 2)

The antibody or antigen-binding fragment thereof of claim 1 or 2, wherein said CLDN18.2 is present on cancer cells.

### Claim 4 (depends on 3)

The antibody or antigen-binding fragment thereof of claim 3, wherein said cancer cells are CLDN18.2 expressing cancer cells.

### Claim 5 (depends on 3, 4)

The antibody or antigen-binding fragment thereof of claim 3 or 4, wherein said cancer cells are selected from the group consisting of gastric, esophageal, pancreatic, lung, ovarian, colon, hepatic, head-neck, and gallbladder cancer cells.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The antibody or antigen-binding fragment thereof of any one of claims 1 to 5 which does not bind to non-cancerous cells except stomach epithelial cells.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The antibody or antigen-binding fragment thereof of any one of claims 1 to 6 which does not bind to non-cancerous lung cells.

### Claim 8 (depends on 1, 2, 3, 4, 5)

The antibody of any one of claims 1 to 5 which is a chimeric, human or humanized antibody.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The antibody of any one of claims 1 to 8, which is a monoclonal antibody.

### Claim 10

An antibody selected from the group consisting of:
(i) an antibody produced by or obtainable from a clone deposited under the accession no. DSM ACC3144 (muAB 43-14A) or DSM ACC3143 (muAB 35-22A),
(ii) an antibody which is a chimerized or humanized form of the antibody under (i),
(iii) an antibody which has the specificity of the antibody under (i), and
(iv) an antibody comprising the antigen binding portion or antigen binding site of the antibody under (i), or
an antigen-binding fragment of the antibody under any one of (i) to (iv).

### Claim 11 (depends on 10)

The antibody of claim 10, wherein the antigen binding portion or antigen binding site of the antibody under (i) comprises the variable region of the antibody under (i).

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A conjugate comprising an antibody or antigen-binding fragment of any one of claims 1 to 11 coupled to at least one detectable label.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A hybridoma capable of producing the antibody of any one of claims 1 to 11.

### Claim 14

A hybridoma deposited under the accession no. DSM ACC3144 (muAB 43-14A) or DSM ACC3143 (muAB 35-22A).

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method for detecting CLDN18.2 or determining the quantity of CLDN18.2 in a sample comprising the steps of:
(i) contacting a sample with the antibody or antigen-binding fragment of any one of claims 1 to 11 or the conjugate of claim 12 and
(ii) detecting the formation of a complex or determining the quantity of a complex between the antibody, the antigen-binding fragment or the conjugate and CLDN18.2.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method for determining whether cells express CLDN18.2 comprising the steps of:
(i) contacting a cellular sample with the antibody or antigen-binding fragment of any one of claims 1 to 11 or the conjugate of claim 12 and
(ii) detecting the formation of a complex between the antibody, the antigen-binding fragment or the conjugate and CLDN18.2 expressed by cells in said sample.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method for diagnosis, detection or monitoring of cancer comprising the steps of:
(i) contacting a biological sample with the antibody or antigen-binding fragment of any one of claims 1 to 11 or the conjugate of claim 12 and
(ii) detecting the formation of a complex and/or determining the quantity of a complex between the antibody, the antigen-binding fragment or the conjugate and CLDN18.2.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method for determining whether a cancer is treatable by a cancer therapy targeting CLDN18.2 comprising the steps of:
(i) contacting a sample comprising cancer cells with the antibody or antigen-binding fragment of any one of claims 1 to 11 or the conjugate of claim 12 and
(ii) detecting the formation of a complex between the antibody, the antigen-binding fragment or the conjugate and CLDN18.2.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A diagnostic test kit which comprises the antibody or antigen-binding fragment of any one of claims 1 to 11 or the conjugate of claim 12.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The antibody or antigen-binding fragment of any one of claims 1 to 11, the conjugate of claim 12, the hybridoma of claim 13 or 14, or the method of any one of claims 15 to 18, wherein said CLDN18.2 comprises the amino acid sequence according to SEQ ID NO: 2 of the sequence listing or a variant of said amino acid sequence.
